Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Czuczman, MS; Leonard, JP; Jung, S; Johnson, JL; Hsi, ED; Byrd, JC; Cheson, BD

Published Date

  • November 1, 2018

Published In

Volume / Issue

  • 29 / 11

Start / End Page

  • 2271 -

PubMed ID

  • 29390097

Pubmed Central ID

  • 29390097

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdx812

Language

  • eng

Conference Location

  • England